marked.bio

EGFR TKI (brain-penetrant) · small molecule

WSD0922

4 active trials, targeting EGFR/EGFRvIII. Not approved for any biomarker on marked.bio yet.

Also known as WSD0922-FU.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 4 4 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of WSD0922.

  1. Wayshine Biopharm 2

Trials

4 of 4 trials shown

  1. Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

    Recruiting Phase 2 Mayo Clinic Started 2026Primary completion 2036-08 NCT07708961

    WSD0922temozolomide

    Glioblastomas must have a pathogenic EGFR mutation, with or without EGFR amplification, detected by Clinical Laboratory Improvement Act (CLI…

    EGFR exon 19 deletion / L858RGlioblastoma, IDH-Wildtype

  2. A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

    Recruiting Phase 2 Wayshine Biopharm Started 2025Primary completion 2027-09 NCT06868485

    WSD0922

    Documented EGFR mutation .

    EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

  3. A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

    Recruiting Phase 1/2 Wayshine Biopharm Started 2024Primary completion 2027-06 NCT06631989

    WSD0922

    A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

    EGFR exon 19 deletion / L858REGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

  4. WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

    Active, not recruiting Phase 1 Mayo Clinic Started 2019Primary completion 2022-10 NCT04197934

    WSD0922

    GBM/AA must either EGFR amplification and/or any activating EGFR mutation (e.g.

    EGFR exon 19 deletion / L858RAnaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System